▶ KPV · SUBTOPIC · MECHANISM
KPV Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Lys-Pro-Val · C-terminal tripeptide of alpha-MSH. Retains the anti-inflammatory activity of the parent hormone without its melanogenic activity. Mechanisms include melanocortin-receptor signaling and direct intracellular NF-kappaB inhibition. Studied in DSS colitis and dermatologic inflammation.
PHARMACOKINETIC HALF-LIFE
Reported half-life for KPV: Short (minutes) plasma · longer tissue retention reported. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
KPV is a defined sequence: Lys-Pro-Val. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
KPV is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
Anti-inflammatory peptides act on cytokine signaling, NF-kappaB activation, mast-cell degranulation, and leukocyte trafficking. KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH and retains the anti-inflammatory activity of the parent hormone without its melanogenic activity. Mechanisms include melanocortin receptor signaling and direct intracellular inhibition of NF-kappaB. Research applications span inflammatory bowel disease and dermatologic inflammation.
The melanocortin axis comprises five G-protein-coupled receptors (MC1R-MC5R) activated by alpha-MSH and ACTH-derived ligands. MC4R drives appetite, energy expenditure, and sexual function via central hypothalamic neurons. PT-141 (bremelanotide) is the FDA-approved MC4R agonist (Vyleesi, 2019). MC1R drives melanocyte pigmentation. KPV (Lys-Pro-Val), the C-terminal alpha-MSH tripeptide, retains anti-inflammatory activity without melanogenic activity.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Brzoska review (PMID 18483175) summarizes multi-paper evidence of KPV anti-inflammatory activity in dermatologic and intestinal models.
Kannengiesser 2008 (PMID 18067137) reported KPV amelioration of intestinal inflammation in DSS colitis.
Small pilot human trials only. No completed Phase 3 evidence.
MECHANISM Q+A
▶ How does KPV work?
Proposed mechanisms include melanocortin receptor signaling (MC1R, MC5R) and direct intracellular inhibition of NF-kappaB activation. The molecule is small enough to cross epithelial barriers including the intestinal mucosa, enabling oral and topical research applications.
▶ What's the half-life of KPV?
Short plasma half-life (minutes). Tissue retention is reportedly longer. Research protocols use frequent dosing or topical/oral routes to maintain target-tissue exposure.
▶ Can KPV be combined with BPC-157?
Different mechanisms; combination is theoretical. KPV acts on inflammatory cytokine signaling and NF-kappaB. BPC-157 acts on tissue-repair pathways (VEGF angiogenesis, GHR upregulation). The two are independent and theoretically complementary in gut-repair research contexts. No published combination RCT exists.
CITED LITERATURE
- Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008. PMID 18483175. link
- Kannengiesser K, Maaser C, Heidemann J, et al.. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. PMID 18067137. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25